John and Erik have devoted their careers to enhancing human health by pioneering advanced pharmaceuticals and innovative R&D tools. Their efforts have significantly contributed to the development of new medicines, the Human Genome Project, DNA arrays, microfluidic assays for proteomics, AI-assisted drug discovery, and numerous analytical techniques. Throughout their tenure at companies ranging from 1 to 100,000 employees, they have maintained their entrepreneurial spirit, fueled by a commitment to vision, innovation, and resilience.
Their first collaboration was at Cell Biosciences (now ProteinSimple), where as early team members, they helped develop a comprehensive suite of protein analysis tools now utilized in thousands of academic and industrial labs. ). They collaborated for many years at Intabio, developing a breakthrough multi-attribute monitoring system for biopharma development and manufacturing, and worked together to advance the technology before the company was sold to Danaher in 2020.
They are very excited to be working together again, this time on a groundbreaking pharmaceutical platform aimed at transforming the production and cost of biologic medicines and antimicrobials.